Details for New Drug Application (NDA): 077965
✉ Email this page to a colleague
NDA 077965 describes NORTRIPTYLINE HYDROCHLORIDE, which is a drug marketed by Ani Pharms, Aurobindo Pharma Ltd, Dr Reddys Labs Sa, Rising, Taro, Teva, Zydus Lifesciences, Pharm Assoc, and Rubicon, and is included in eleven NDAs. It is available from twenty-seven suppliers. Additional details are available on the NORTRIPTYLINE HYDROCHLORIDE profile page.
The generic ingredient in NORTRIPTYLINE HYDROCHLORIDE is nortriptyline hydrochloride. There are twelve drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the nortriptyline hydrochloride profile page.
The generic ingredient in NORTRIPTYLINE HYDROCHLORIDE is nortriptyline hydrochloride. There are twelve drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the nortriptyline hydrochloride profile page.
Summary for 077965
| Tradename: | NORTRIPTYLINE HYDROCHLORIDE |
| Applicant: | Taro |
| Ingredient: | nortriptyline hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 077965
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;ORAL | Strength | EQ 10MG BASE/5ML | ||||
| Approval Date: | Jun 20, 2006 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
